Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 4/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19485538 | 0.83 | PARP10 (0.36) | SLC6A4KMT2AAPPPARP10CA1 | |
| SCHEMBL28772088 | 0.82 | PARP10 (0.41) | SLC6A4KMT2AAPPPARP10CA1 | |
| SCHEMBL8723823 | 0.80 | ACHE (0.42) | KMT2A | |
| SCHEMBL18260812 | 0.78 | CA1 (0.38) | SLC6A4KMT2AAPPPARP10CA1 | |
| SCHEMBL25325632 | 0.77 | LMNA (0.48) | KMT2A | |
| SCHEMBL256381 | 0.77 | ALDH1A3 (0.52) | SLC6A4KMT2AAPPPARP10CA1 | |
| SCHEMBL2771834 | 0.75 | PARP10 (0.36) | SLC6A4KMT2AAPPPARP10CA1 | |
| SCHEMBL20252416 | 0.75 | ALDH1A1 (0.44) | KMT2APARP10 | |
| SCHEMBL28556902 | 0.74 | PARP10 (0.43) | KMT2AAPPPARP10CA1CA2 | |
| SCHEMBL15300858 | 0.72 | SLC6A4 (0.39) | SLC6A4KMT2AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | CPT1B, CLCN2, TNNC1 | SLC6A4 1186/4885KMT2A 3478/4885APP 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.